Hyesoo Hwangbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyesoo Hwangbo has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Huanhuan Sun
3 shared publications- Kiwon Ban
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China
3 shared publications Yimin Lai
3 shared publications- Aoyang Pu
Department of Biomedical Sciences, City University of Hong Kong, Kowloon, China
2 shared publications - Hae-Won Kim
Institute of Tissue Regeneration Engineering (ITREN), Dankook University, Cheonan, Republic of Korea
2 shared publications - Hun-Jun Park
Department of biomedicine and health sciences, The Catholic University of Korea, Seoul 06591, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Host-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHost-compatible cardiac fibroblast-derived ECM patches promote myocardial repair after infarction
Cardiac extracellular matrix (ECM) patches provide tissue-specific environments for localized cell delivery after myocardial infarction (MI), but their translation is limited by reliance on xenogeneic tissues or non-cardiac ECM sources. Here, we developed a scalable cardiac fibroblast (CF)-derived ECM patch that combines cardiac-associated matrix cues with improved host compatibility. A matrix-stimulatory cocktail and three-dimensional PLGA mesh culture system enhanced ECM production by multiple matrix-secreting cell types and enabled fabrication of transplantable patches. Transcriptomic and proteomic analyses demonstrated cardiac-associated signatures in human induced pluripotent stem cell-derived CFs and their ECM patches compared with non-cardiac fibroblast controls. In immunocompetent rats, same-strain rat CF-derived ECM patches induced less myocardial macrophage infiltration than xenogeneic human CF-derived patches. Mesenchymal stromal cell-loaded, same-strain CF-derived ECM patches produced sustained functional improvement, increased vascularization and viable myocardium, and reduced fibrosis after MI without systemic immunosuppression. These findings identify host compatibility as an important determinant of ECM patch-mediated cell therapy and establish CF-derived ECM as a promising platform for myocardial repair, with future potential for patient-derived and immune-matched applications.
- Open Access
- 19 May 2026
- Published by SAGE Publications in Journal of Tissue Engineering
- Vol. 17
Cell-free therapy for alopecia via the secretome of hiPSC-derived dermal papilla cells
Alopecia is highly prevalent and debilitating, yet current drugs provide limited, reversible benefit with notable side effects. We established a rapid protocol to generate human induced pluripotent stem cell–derived dermal papilla cells (hiPSC-DPCs) and demonstrated that their conditioned medium (CM) acts as a potent, cell-free hair-regenerative therapy. Transdermal delivery of hiPSC-DPCs or CM accelerated anagen re-entry and hair regrowth in depilated mice, and hiPSC-DPC CM outperformed minoxidil in promoting ex vivo hair-shaft elongation and in vitro proliferation and migration of primary DPCs and keratinocytes. Proteomic and metabolomic profiling revealed enrichment of growth factors, antioxidants, and immunomodulatory metabolites linked to TNF and PI3K–Akt signaling, conferring superior anti-inflammatory and cytoprotective properties relative to primary DPC CM. Moreover, hiPSC-DPC CM mitigated dihydrotestosterone (DHT)-induced pathology by suppressing androgen receptor expression and nuclear translocation. These findings position hiPSC-DPC secretome as a dual-functional, regenerative, and anti-androgenic biologic with translational potential for durable alopecia treatment.
- 19 May 2026
- Published by SAGE Publications in Journal of Tissue Engineering
- Vol. 17
Open AccessCell-free therapy for alopecia via the secretome of hiPSC-derived dermal papilla cells
Alopecia is highly prevalent and debilitating, yet current drugs provide limited, reversible benefit with notable side effects. We established a rapid protocol to generate human induced pluripotent stem cell–derived dermal papilla cells (hiPSC-DPCs) and demonstrated that their conditioned medium (CM) acts as a potent, cell-free hair-regenerative therapy. Transdermal delivery of hiPSC-DPCs or CM accelerated anagen re-entry and hair regrowth in depilated mice, and hiPSC-DPC CM outperformed minoxidil in promoting ex vivo hair-shaft elongation and in vitro proliferation and migration of primary DPCs and keratinocytes. Proteomic and metabolomic profiling revealed enrichment of growth factors, antioxidants, and immunomodulatory metabolites linked to TNF and PI3K–Akt signaling, conferring superior anti-inflammatory and cytoprotective properties relative to primary DPC CM. Moreover, hiPSC-DPC CM mitigated dihydrotestosterone (DHT)-induced pathology by suppressing androgen receptor expression and nuclear translocation. These findings position hiPSC-DPC secretome as a dual-functional, regenerative, and anti-androgenic biologic with translational potential for durable alopecia treatment.
- Open Access
- 1 November 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 53, 366-385
Single-atom Pt-doped ceria nanozymes mitigate myocardial ischemia reperfusion injury via cardiomyocyte-targeted uptake and suppression of reactive oxygen species
The primary treatment for myocardial infarction (MI) is restoring blood flow to the obstructed coronary artery. However, this approach can paradoxically generate reactive oxygen species (ROS), leading to secondary ischemia-reperfusion (IR) injury. Multifunctional nanomaterials present a promising alternative for managing IR injury, offering benefits including cost-effectiveness, robust catalytic stability, and customizable properties that surpass traditional antioxidants. This study explores single-atom Pt-doped ceria nanozymes (Pt@CeNZ) with multi-enzyme mimetic functions facilitated by atomically dispersed Pt. The nanozymes effectively eliminate excess ROS in cardiomyocytes, thereby enhancing cell viability. Notably, Pt@CeNZ demonstrates significantly higher uptake in cardiomyocytes, underscoring its potential as a targeted nanotherapeutic for cardiac tissues. In vivo studies further confirm that Pt@CeNZ treatment substantially reduces infarct size and improves cardiac function following IR injury, without inducing long-term toxicity or inflammation. These findings position Pt@CeNZ as a highly promising heart-targeting nanotherapeutic with potential applications in the acute and long-term treatment of cardiac injuries.
- 1 November 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 53, 366-385
Open AccessSingle-atom Pt-doped ceria nanozymes mitigate myocardial ischemia reperfusion injury via cardiomyocyte-targeted uptake and suppression of reactive oxygen species
The primary treatment for myocardial infarction (MI) is restoring blood flow to the obstructed coronary artery. However, this approach can paradoxically generate reactive oxygen species (ROS), leading to secondary ischemia-reperfusion (IR) injury. Multifunctional nanomaterials present a promising alternative for managing IR injury, offering benefits including cost-effectiveness, robust catalytic stability, and customizable properties that surpass traditional antioxidants. This study explores single-atom Pt-doped ceria nanozymes (Pt@CeNZ) with multi-enzyme mimetic functions facilitated by atomically dispersed Pt. The nanozymes effectively eliminate excess ROS in cardiomyocytes, thereby enhancing cell viability. Notably, Pt@CeNZ demonstrates significantly higher uptake in cardiomyocytes, underscoring its potential as a targeted nanotherapeutic for cardiac tissues. In vivo studies further confirm that Pt@CeNZ treatment substantially reduces infarct size and improves cardiac function following IR injury, without inducing long-term toxicity or inflammation. These findings position Pt@CeNZ as a highly promising heart-targeting nanotherapeutic with potential applications in the acute and long-term treatment of cardiac injuries.
- Open Access
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (8) , 499-518
The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health
Bui TV, et al. Korean Circ J. 2023 Jun;53:e51. https://doi.org/10.4070/kcj.2023.0048
- 1 January 2023
- Published by XMLink in Korean Circulation Journal
- Vol. 53 (8) , 499-518
Open AccessThe Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health
Bui TV, et al. Korean Circ J. 2023 Jun;53:e51. https://doi.org/10.4070/kcj.2023.0048